New Meningococcal Vaccine Product Available: MenQuadfi (MenACWY-TT)
MnVFC providers have another meningococcal product available to order though the MnVFC program. MenQuadfi (MenACWY-TT) is a meningoccal (groups A, C, W, Y) conjugate vaccine manufactured by Sanofi Pasteur. This vaccine is approved for people ages 2 years and older, including people older than 55 years of age.
Dosage and administration information
Dose: 0.5mL administered intramuscular (single dose vial). Per the CDC 2021 Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger:
- Routine vaccination
- 2-dose series at 11–12 years, 16 years
- Catch-up vaccination
- Age 13–15 years: 1 dose now and booster at age 16–18 years (minimum interval: 8 weeks)
- Age 16–18 years: 1 dose
Refer to the immunization schedule notes section for special situations (i.e., asplenia, travel, first-year college students, etc.).
Contraindications: Severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.
Storage and handling
Store MenQuadfi at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Do not freeze (and do not use vaccine that has been frozen). Do not use after the expiration date. Rubber vial stopper does not contain latex.
Other MenACWY products
Pay close attention when ordering MenACWY vaccine products. Sanofi Pasteur has another MenACWY product (MenACWY-D/Menactra) for ages 9 months to 55 years. The packaging for both of the Sanofi Pastuer products look very similar. GlaxoSmithKline's (GSK) MenACWY product (MenACWY-CRM/Menveo) is licensed for ages 2 months to 55 years. Consider ordering and storing one MenACWY product to avoid confusion and vaccine errors.
Resources
You are subscribed to MnVFC Announcements for the Minnesota Department of Health. A printable version of this information is available on MnVFC Announcements.
|
